Cadila Pharma expands oncology portfolio with Tarzed
05 January 2022 | News
TARZED is available as 440 mg injection
Ahmedabad-based Cadila Pharmaceuticals has launched Trastuzumab, with the brand name TARZED.
Tarzed is a humanised monoclonal antibody, recommended in HER2 Positive early breast cancer and metastatic breast cancer.
According to the latest audit report of Globocan, Incidences of Breast Cancer are highest among all types of Cancers in the Indian Population.
In a commitment to further strengthening the oncology portfolio Cadila’s TARZED is available as 440 mg injection. The pharma giant has always been focussed on making sure high-quality, affordable, and life-saving treatments are within the reach of patients. TARZED is considered safe and more efficacious compared to conventional treatment medicines for breast cancer.
